1. APS

2. Investigators & Sites

3. APS Background

4. Study Hypotheses

5. APS Primary End Points

6. APS Secondary End Points

7. APS Methods Inclusion Criteria

8. APS Methods Exclusion Criteria

9. APS Methods Study Procedures

10. APS Methods Study Procedures

11. APS Methods Ultrafiltration Device

12. APS Baseline Demographics and Comorbidities

13. APS Baseline Heart Failure Characteristics

14. APS Baseline Functional Capacity and Vital Signs

15. APS Baseline Laboratory Values

16. APS Baseline Medications

17. APS

18. Primary End Point Weight Loss at 48 Hr

19. APS Primary End Point Dyspnea Score at 48 Hr

20. APS Secondary End Point Net Fluid Loss at 48 Hr

21. APS Worsening Heart Failure in 90 days

22. APS Freedom From Re-hospitalization for Heart Failure

23. APS Secondary End Points

24. APS Safety End Points: Change in Serum Creatinine

25. APS Adverse events up to 90 days

26. APS Deaths up to 90 days

27. APS Safety End Points

28. APS Vasoactive Drugs Requirement

29. APSSummary

30. Conclusions